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Sudden cardiac death (SCD) remains one of the most prevalent modes of death in industrialized 
countries, and myocardial ischemia due to thrombotic coronary occlusion is its primary cause. 
The role of platelets in the occurrence of SCD extends beyond coronary flow impairment by 
clot formation. Here we review the substances released by platelets during clot formation and 
their arrhythmic properties. Platelet products are released from three types of platelet granules: 
dense core granules, alpha-granules, and platelet lysosomes. The physiologic properties of dense 
granule products are of special interest as a potential source of arrhythmic substances. They are 
released readily upon activation and contain high concentrations of serotonin, histamine, purines, 
pyrimidines, and ions such as calcium and magnesium. Potential arrhythmic mechanisms of 
these substances, e.g., serotonin and high energy phosphates, include induction of coronary 
constriction, calcium overloading, and induction of delayed after-depolarizations. Alpha-granules 
produce thromboxanes and other arachidonic-acid products with many potential arrhythmic 
effects mediated by interference with cardiac sodium, calcium, and potassium channels. Alpha-
granules also contain hundreds of proteins that could potentially serve as ligands to receptors on 
cardiomyocytes. Lysosomal products probably do not have an important arrhythmic effect. Platelet 
products and ischemia can induce coronary permeability, thereby enhancing interaction with 
surrounding cardiomyocytes. Antiplatelet therapy is known to improve survival after myocardial 
infarction. Although an important part of this effect results from prevention of coronary clot 
formation, there is evidence to suggest that antiplatelet therapy also induces anti-arrhythmic 
effects during ischemia by preventing the release of platelet activation products.
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(Akar and Akar, 2007). These events create a hostile environment 
that renders the myocardium prone to arrhythmias (Coronel et al., 
1991).
Ventricular fibrillation during ischemia results from re-entrant 
excitation. Onset of re-entry may not only result from injury cur-
rent (Lown and Wolf, 1971; Verkerk et al., 2000), but may also be 
evoked by triggered beats originating from early and delayed after-
potentials (EADs and DADs; Ter Keurs and Boyden, 2007).
Platelets play an important role in the occurrence of SCD. 
Traditionally, the role of platelets in SCD was believed to be limited 
to their ability to halt coronary flow by clot formation. However, 
there is an increasing body of evidence suggesting that the process of 
clot formation has arrhythmic properties beyond the arrest of distal 
perfusion. Animal experiments have shown that platelet activation 
increases the susceptibility of ischemic myocardium to VF. Coronel 
et al. (1997) showed that intracoronary thrombi have profibrilla-
tory effects. In their pig model, the left anterior descending artery 
(LAD) was ligated, and blood with thrombin-induced platelet acti-
vation or heparinized blood injected distally. Notwithstanding a 
comparable area of ischemia, thrombi injection resulted in VF in 
4/7 pigs vs. 2/19 control pigs. Similarly, in a dog model of regional 
myocardial ischemia, 51% of control animals developed VF after 
coronary artery embolization. However, following pre-treatment 
with carbenicillin, a strong inhibitor of platelet aggregation, or 
estradiol cypionate, which induces severe   thrombocytopenia, the 
CardiaC arrhythmias
Sudden cardiac death (SCD) remains one of the most prevalent 
modes of death in industrialized countries, claiming almost a mil-
lion deaths annually in Western Europe and the United States (Zipes 
et al., 2006; Chugh et al., 2008). Ventricular fibrillation (VF) in the 
setting of coronary artery disease is the most common underly-
ing arrhythmia (Zipes et al., 2006) as acute coronary thrombosis 
is observed in 74–79% of SCD victims at autopsy (Davies and 
Thomas, 1984; Frink et al., 1988).
Arrest of blood flow to the myocytes results in a complex 
ischemic reaction that includes an increase in outward potassium 
current (Wilde et al., 1990), a triphasic increase of extracellular 
potassium (Coronel et al., 1988), a decrease of action potential 
(AP) duration (Saito et al., 2005), and depolarization of resting 
membrane potential. Decrease in pH results in activation of the 
Na+–H+ exchange pathway extruding H+ from the cell. This leads to 
Ca2+ loading as a consequence of reverse-mode action of the Na–Ca 
exchanger (NXC; Dekker et al., 1996; Akar and Akar, 2007). Ca2+ 
loading of ischemic cardiomyocytes has several pro-arrhythmic 
effects: abnormal sarcoplasmic reticulum Ca2+ cycling and promo-
tion of AP alternans, delayed after-depolarizations (DADs), and 
decreased gap-junction conductance ultimately leading to uncou-
pling of cell-to-cell connections (Kléber et al., 1987). Furthermore, 
reactive oxygen species are released, resulting in changes in ion 
channel function (Carmeliet, 1999) and mitochondrial dysfunction 
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plaque rupture results in exposure of subendothelium-containing 
collagen, collagen-bound-von Willebrand factor (vWf), fibronectin, 
and laminin. Platelet membranes expose an array of adherence pro-
teins waiting to adhere with these exposed molecules. Upon adhesion, 
intracellular signal transduction pathways are activated. Granules 
fuse with the platelet membrane leading to a platelet-shape change, 
expulsion of granule contents and exposure of formerly intragranular 
membrane molecules on the outside of the platelet. Amongst these 
are glycoprotein 1b/V/IX and glycoprotein αIIbβ3 receptors which 
mediate platelet aggregation and finally clot formation.
Three types of platelet granules are morphologically distinct 
(Figure 2; Table 1): dense core granules (δ-granules), alpha-gran-
ules, and platelet lysosomes (λ-granules; Rendu and Brohard-
Bohn, 2001).
About three to eight dense granules are present per platelet. They 
are inherently electron dense when viewed in electron microscopy. 
Dense granules are acidic (pH 6.1) and contain platelet agonists 
incidence of VF was reduced to 9% and 0, respectively (Johnson 
et al., 1981). Platelet activation results in the release of platelet prod-
ucts, the so-called secretome, which includes organic substances 
[e.g., adenosine-5′-triphosphate (ATP), serotonin, and histamine] 
and more than 2000 proteins (Coppinger et al., 2004). Many of these 
substances can alter electrophysiological properties of the heart in 
various animal species, supporting the notion that activated plate-
lets exert pro-arrhythmic effects (Figure 1; Hoffman et al., 1996, 
1997; Flores et al., 1999). Conversely, platelet antagonists counteract 
ischemia-induced arrhythmias in animal studies (Wainwright et al., 
1989; Ahn et al., 1999).
Platelet adhesion and aCtivation
Platelets are small anuclear cells (2–3 μm, 7.5–1.5 fL), which are 
derived from defragmentation of megakaryocytes. Platelets have a 
life-span of 8–12 days, and the blood of healthy individuals has a 
platelet concentration of 150–400 × 109/L (Greer, 2008). Coronary 
Figure 1 | Mechanisms by which platelet activation and release of platelet products could induce arrhythmias during ischemia. ADP/ATP , adenosine 
diphosphate, adenosine triphosphate; EETs, epoxyeicosatrienoic acids; 5-HT, 5-hydroxytryptamine (serotonin); TNF-α, tumor necrosis factor-α.www.frontiersin.org  December 2010  | Volume 1  | Article 166  |  3
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65 mM (Holmsen and Weiss, 1979), whereas (platelet-rich) plasma 
  serotonin   concentration was 842 ± 58 nmol/L in healthy individuals 
(Vikenes et al., 1999). Serotonin can be used to assess the platelet 
release reaction: it locally increased 18- to 27-fold from normal 
levels in tissue surrounding a coronary thrombus in a dog model 
(Ashton et al., 1986).
Human atrial and ventricular cardiomyocytes express 5-HT4 
receptors (Kaumann et al., 1990; Bach et al., 2001), and exposure 
to serotonin results in tachycardia, increased atrial contractility, 
and atrial arrhythmias (Kaumann and Levy, 2006). 5-HT causes 
an up to sixfold increase in L-type Ca2+ channel current through 
5-HT4 receptors, in atrial myocytes from patients in sinus rhythm 
(Ouadid et al., 1992; Pau et al., 2003). Likewise, serotonin has posi-
tive inotropic and lusitropic effects on ventricular cardiomyocytes 
(Brattelid et al., 2004). Arrhythmic effects have also been observed 
and are probably mainly related to Ca2+-overload mediated by an 
increase in L-type Ca2+ current (Kaumann, 1994). Antidepressants 
from the selective serotonin reuptake inhibitor class (SSRI) have 
QT prolonging effects in patients with SSRI intoxications. The 
major clinical interaction with cardiovascular disease is likely its 
platelet inhibiting effect, which may reduce incidence of MI (Sauer 
et al., 2003).
Like, serotonin, histamine is another amine present in dense 
granules. Resting human platelets contain 25 ng histamine/108 
platelets, which can increase toward 47 ng/108 platelets upon plate-
let activation (Jancinová and Nosál, 1998). The major arrhythmic 
effects of histamine consist of H1-receptor mediated slowing of AV 
nodal conduction and H2-receptor mediated increase in sinus rate 
and ventricular automaticity (Wolff and Levi, 1986). Histamine 
also has a positive inotropic effect on ventricular cardiomyocytes 
(Ginsburg et al., 1980).
In addition to serotonin, histamine can also cause vasoconstric-
tion as further discussed below.
Nucleotide derivatives
Extracellular purines (adenosines, ADP, and ATP) and pyrimidines 
[uridine diphosphate (UDP) and uridine triphosphate (UTP)] can 
initiate a wide range of intracellular signaling cascades through 
purinergic receptors (Ralevic and Burnstock, 1998). Platelet-dense 
granules contain a high concentration of ATP (436 mM) and ADP 
(653 mM; Holmsen and Weiss, 1979), which can accelerate platelet 
activation binding to ADP receptors upon release. Normal extracel-
lular ATP concentration is about 2 μM (Born and Kratzer, 1984) and 
may increase to 100 μM under pathological conditions (Coade and 
Pearson, 1989). Under normal conditions, ATP is rapidly converted 
to adenosine (Flores et al., 1999).
In rat and mouse ventricular cardiomyocytes, exposure to ATP 
induces a cytosolic Ca2+ rise and has positive inotropic effects 
(Danziger et al., 1988; Pucéat et al., 1991; Mei and Liang, 2001). By 
activation of purinergic receptors, ATP induces sustained increases 
in diastolic Ca2+ and triggers multiple Ca2+ waves, leading to DADs 
in current clamped mouse hearts (Gurung et al., 2009).
Ions
The dense granular concentration of calcium was calculated to be 
2.2 M (Holmsen and Weiss, 1979). The total amount of calcium in 
human platelets is 10.1 μmol/1011 platelets (Meyers et al., 1982). In 
that serve to amplify platelet activation. They are the most rapidly 
secreted granules and release, amongst others, adenosine diphos-
phate (ADP), ATP, guanosine 5′-triphosphate (GTP), guanosine 
diphosphate (GDP), Ca2+, magnesium pyrophosphate, and amines 
such as serotonin and histamine. After exocytosis, ADP acts as a 
platelet agonist and is important in the activation of additional 
circulating platelets (McNicol and Israels, 1999).
Alpha-granules release various proteins involved in plate-
let interaction. Proteomic studies of the platelet secretome have 
yielded a list of more than 2000 of such proteins (Coppinger et al., 
2004; McRedmond et al., 2004). These proteins are involved in 
platelet interactions (glycoprotein αIIbβ3 receptor, fibrinogen, vWF, 
thrombospondin-I, fibronectin, vitronectin, GAS6), coagulation 
and fibrinolysis (plasminogen, plasminogen activator inhibitor-1, 
protein S), and chemotaxis and cell signaling (transforming growth 
factor-β, platelet-derived growth factor; Gresele et  al., 2002). 
Some of the proteins are known as markers of platelet activation 
(P-selectin, β-thromboglobulin, platelet factor 4). Alpha-granules 
also contain plasma proteins such as albumin, vWF antigen II, 
immunoglobulins, plasma protease inhibitors, and histidine-rich 
glycoprotein.
Finally, lysosomes release clearing factors such as cathep-
sins, proteases, and glycohydrolases. Lysosome-release requires 
a stronger type of stimulus, such as thrombin or high doses of 
collagen, whereas alpha- and dense-granules are readily released 
with weaker types of stimulation, such as platelet exposure to ADP 
(Gresele et al., 2002).
eleCtroPhysiologiCal effeCts of aCtivated Platelet ProduCts
Many of the substances released by platelets can alter the elec-
trophysiological properties of the heart in various animal species 
(Flores et al., 1999).
Amines
Serotonin or 5-hydroxytryptamine (5-HT) is not synthesized 
in platelets but is actively taken up from the plasma and accu-
mulated in dense granules where it is likely complexed with ATP 
and potentially with calcium (De Clerck et al., 1984). The serot-
onin released by exocytosis is relatively stable and functions as a 
weak platelet agonist on 5HT2 receptors (De Clerck et al., 1984), 
although it is probably less important in this respect than ADP. 
The positive feedback effect of serotonin may be of secondary 
importance to its vasoconstrictive action, which reduces flow at 
the site of injury and thereby limits blood loss (De Clerck, 1986). 
Dense granular concentration of serotonin was calculated to be 
Figure 2 | Schematic drawing of a single platelet and its contents.Frontiers in Physiology  | Cardiac Electrophysiology    December 2010  | Volume 1  | Article 166  |  4
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small. The platelets in 1 mL blood (about 250 × 109) contain about 
25.3 nmol of Ca2+, and upon release would increase the local Ca2+ 
concentration by about 2% (presuming a volume of dispersion 
of 1 mL). This raw estimate does not take into account the high 
concentration of platelets in an actual thrombus and the washout 
of Ca2+ during the non-occlusive phase of thrombus formation.
The platelet content of Mg2+, the second most abundant ion, 
is much smaller that the Ca2+ content. Platelets contain about 
0.4 μmol/1011 platelets of releasable magnesium (Meyers et al., 
1982). Normal plasma concentrations of Mg2+ range between 0.6 
and 0.7 mmol/L. A large influence of platelet Mg2+ release during 
platelet aggregation is therefore less likely than it is for Ca2+.
Thromboxane, arachidonic acid, and other alpha-granule contents
During platelet activation, arachidonic acid is liberated by phos-
pholipase-A2 from membrane phospholipids and is converted 
enzymatically to epoxyeicosatrienoic acids (EETs) via the cyclooxy-
genase and lipoxygenase pathways. EETs have several effects on 
cardiac tissues (Flores and Sheridan, 1990; Xiao, 2007). EETs inhibit 
cardiac Na+ channels (Lee et al., 1999), significantly increase intra-
cellular Ca2+ concentrations in isolated guinea pig cardiomyocytes 
(Moffat et al., 1993), and significantly modulate the activities of 
cardiac Ca2+ channels (Chen et al., 1999) and KATP channels (Lee 
et al., 1999). Furthermore EETs can uncouple neonatal rat car-
diac myocytes by reducing gap-junction conductance (Massey 
et al., 1992).
Thromboxane is an arachidonic-acid derivative that is pro-
thrombotic and released by platelets. Thromboxane is produced 
by cyclooxygenase from prostanoids, a process that is inhibited by 
aspirin. Thromboxane is chemically unstable in blood, but its stable 
analog, U41669, has been shown to increase automaticity and to 
increase both resting and peak intracellular Ca2+ concentrations and 
induce irregular Ca2+ transients in isolated neonatal rat ventricular 
myocytes (Hoffmann et al., 1993). This is supported by the fact that 
these effects can be reversed in rabbit cardiomyocytes by blockade 
of U41669 (Wacker et al., 2009).
Chien et al. examined the effects of platelet products of rab-
bit platelets on cytosolic calcium in chick embryonic heart cells. 
They identified the arrhythmic platelet product(s) as small 
  trypsin-sensitive peptide(s) (Chien et al., 1990). Examples of such 
small peptides, found in alpha-granules, are substance P, calcitonin, 
vasoactive intestinal peptide, and angiotensinogen. Of the latter 
three no direct cardiac effects have been described. Substance P 
has only recently been found to be present in relatively high con-
centrations in platelets (Jones et al., 2008). It is primarily known 
as a neurotransmitter of pain sensation, but also has cardiovascu-
lar effects which are primarily mediated through vasodilatation. 
However, direct cardiac effects have been described: induction of 
bradycardia and hypotension in denervated and anesthetized rats 
(Tompkins et al., 1999).
Besides these, alpha-granules contain a long list of substances 
(Table 1) which can be subdivided in proteoglycans, adhesive glyco-
proteins, hemostatic factors, cellular mitogens, protease inhibitors, 
and miscellaneous other molecules (Rendu and Brohard-Bohn, 
2001). Platelet proteomic approaches have tried to assess all proteins 
present in platelets (Maguire and Fitzgerald, 2003; McRedmond 
et al., 2004). Proteomics of the products of activated platelets have 
Table 1 | Platelet granules and their contents.
Dense granules  Alpha-granules  Lysosomal granules
Serotonin  Albumin  Cathepsin D
Histamine  Fibrinogen  Cathepsin E
ATP  Fibronectin  Carboxypeptidase A
ADP  Vitronectin  Carboxypeptidase B
Calcium  Osteonectin  Proline carboxypeptidase
Magnesium  Calcitonin  β-N-acetyl-d-hexosaminidase
Pyrophosphate  Von Willebrand Factor  β-d-glucuronidase
  Von Willebrand antigen II  β-d-galactosidase
  Thrombospondin  α-d-mannosidase
  Platelet factor 4  α-l-arabinofuranosidase
  IgG, IgA, IgM  α-d-galactosidase
  C1 inhibitor  α-l-fucosidase
  Plasminogen  β-d-fucosidase
  Plasminogen activator  β-d-glucosidase 
  inhibitor-1
  Platelet-derived  α-d-glucosidase 
  collagenase inhibitor
  High molecular weight  Acid phosphatase 
  kininogen
  Angiotensinogen  Arylsulfatase





  Platelet basic protein
  β-Thromboglobulin
  Histidine-rich  
  glycoprotein
  Connective tissue- 
  activating protein III
  Neutrophil-activating 
  protein II
  Platelet-derived 
  growth factor
  Coagulation factor V
  Coagulation factor VIII
  Substance P
  Vasoactive intestinal  
  peptide
  >300 other proteins  
  (Maguire et al., 2002;  
  Maguire and Fitzgerald,  
  2003; Coppinger  
  et al., 2004)
Table adapted from McNicol and Israels (1999).
humans, arrhythmias related to high calcium and magnesium lev-
els are rare (Diercks et al., 2004). The normal plasma concentration 
of Ca2+ ranges from 1.03 to 1.23 mmol/L (Larsson and Ohman, 
1978). The Ca2+ concentration in dense granules is very high, but 
the amount of released Ca2+ relative to the plasma   concentration is www.frontiersin.org  December 2010  | Volume 1  | Article 166  |  5
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effeCts on myoCardial ContraCtility
Both increases and decreases in myocardial contractility have been 
found in experiments with substances released by platelets. ATP 
has strong positive inotropic effects in rats. ATP stimulates a large 
increase in cytosolic Ca2+ transients (Danziger et al., 1988; Christie 
et al., 1992). ATP also increases the L-type Ca2+ current in rats, and 
both mechanisms can induce positive inotropic effects (Scamps and 
Vassort, 1990). Further upstream in rats and mice, activation of P2 
purinergic receptors exerts a positive inotropic effect on cardio-
myocytes and intact hearts by increasing intracellular ATP levels 
(Mei and Liang, 2001). Thrombin promotes Ca2+ entry and release 
in cardiomyocytes (Chien et al., 1990). Serotonin has positive ino-
tropic effects on the human atria through the HT4 receptor, but 
such a receptor is absent in human ventricular cardiomyocytes 
(Kaumann, 1994).
Negative inotropic effects have been described for tumor necro-
sis factor-α in rats (Edmunds et al., 1999; Tabrizchi, 2001). It is 
likely that these effects leverage toward a positive inotropic effect of 
platelet products, as was confirmed by a study that added aggregat-
ing platelets to a bath of cat papillary muscles resulting in positive 
inotropic effects (Shah et al., 1989). Also, injection of low-dosed 
PAF into coronary arteries resulted in strong positive inotropic 
effects in isolated rabbit hearts (Alloatti et al., 1990).
interaCtion of effeCts of Platelet ProduCts and  
isChemiC effeCts
Arrhythmias are very common during cardiac ischemia and are the 
result of a multifactorial process. Ischemia is the most important 
factor in arrhythmia occurrence. This is evidenced by the fact 
that the absence of active platelets does not completely eliminate 
occurrence of VF in coronary ligation studies described above 
(Johnson et al., 1981; Chien et al., 1990; Coronel et al., 1997). 
Platelet products strongly increase the risk of arrhythmias in the 
setting of myocardial ischemia. It is tempting to speculate which 
platelet products have the strongest role in arrhythmia occurrence. 
From the clinical setting we know that ischemic VF often occurs 
within the first minutes after onset of chest pain, and it’s risk 
declines during the first hours. An arrhythmic mediator should 
therefore be released readily upon platelet activation and exert 
it’s effect within seconds as also has been observed in the animal 
models.
Amines from dense granules are readily released in high con-
centrations and alter cardiomyocyte electrophysiology directly, 
which makes them likely candidates. On top of that serotonin-
induced vasoconstriction could undermine collateral perfusion 
of the ischemic area. As a result of the findings of Chien et al., 
small trypsin-sensitive peptide(s) released by platelets, such as 
substance P, deserves further investigation. Increased endothe-
lial permeability induced by ischemia promotes interaction 
between these substances and cardiomyocytes. An unstable 
thrombus with fragment embolization could lead to increased 
local heterogeneity.
Platelet antagonists and arrhythmia Prevention
Antiplatelet therapy is known to improve survival after myocardial 
infarction (Lau et al., 1992), while patients with increased plate-
let aggregation have a worse prognosis postmyocardial infarction 
revealed more than 300 proteins (Maguire et al., 2002; Coppinger 
et al., 2004) which are mostly secreted in alpha-granules. Most 
of these proteins are present in only small quantities. Large elec-
trophysiologic effects would therefore likely be mediated through 
membrane channels on cardiomyocytes.
Lysosomal products
Platelet lysosomes contain “clearing factors” that breakdown the 
platelet clot: acid proteases and glycohydrolases. These lysosomal 
products have no known effect on cardiomyocytes. Breakdown 
products of platelet clots could potentially be arrhythmogenic, 
however a review on the incidence of early ventricular arrhythmias 
after thrombolytic therapy did not show evidence for increased 
early arrhythmias (Solomon et al., 1993).
vasoConstriCtion
Several dense granule products have been shown to have effects 
on coronary smooth muscle cells that mediate coronary con-
striction. ATP, UTP, and ADP can mediate prostacyclin and 
nitric-oxide release by interaction with the P2Y receptors on 
endothelial cells (da Silva et al., 2009). Serotonin injected in 
coronary arteries of angina patients leads to intense coronary 
constriction (McFadden et al., 1991), probably mediated by 
vascular 5-HT1B and 5-HT2A receptors (Kaumann and Levy, 
2006). Like serotonin, histamine is another strong vasoconstric-
tor. In patients with variant angina, histamine could induce 
coronary spasm in 47% of subjects in one study (Kaski et al., 
1986). Thrombus-released vasoconstrictive substances could 
reduce coronary perfusion and thereby increase local ischemia 
and reduce blood supply by collateral vessels. Ischemia due to 
coronary spasm in the absence of severe atherosclerosis has been 
described as a cause of VF (Seniuk et al., 2002; Al-Sayegh et al., 
2007; Hung et al., 2007; Hendriks et al., 2008; Sanna et al., 2009; 
Sansone et al., 2009).
endothelial Permeability
Increased endothelial permeability during myocardial infarc-
tion can facilitate leakage of platelet products from the coronary 
lumen to epicardial myocytes. Increased endothelial permeability 
could be induced by platelet products or by ischemia. Indeed in 
a rat model of cerebral ischemia, thrombin injection induced 
  vascular   disruption, and increased permeability (Chen et al., 
2010). In another study, platelet activating factor (PAF) greatly 
increased coronary permeability by the inhibition of endogene-
ous NO synthesis (Filep et al., 1993). And, in a hamster model, 
PAF increased permeability of the microvasculature of the cheek 
pouch (Ramírez et al., 1995). Also, serotonin has been shown 
to increase vascular permeability in different animal models 
(Clerck et al., 1984).
Ischemia also induces coronary permeability as animal studies 
have shown. In a dog model, 15 min of coronary occlusion could 
increase protein leakage by 50% (Dauber et al., 1990). And, in a 
rat model, 20 min of severe ischemia increased transcapillary albu-
min flux by 100% (Sunnergren and Rovetto, 1980, 1987). Both the 
direct ischemic effects and the effects induced by platelet products 
promote interaction of platelet products and the myocardial tissue 
surrounding the ischemic coronary.Frontiers in Physiology  | Cardiac Electrophysiology    December 2010  | Volume 1  | Article 166  |  6
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